Workshop on biosimilars

EventCorporateBiosimilars

Dutch is available via eTranslation, the European Commission's machine translation service.

Translate to Dutch | Important information about machine translation

Datum

donderdag, 31 oktober 2013, Hele dag

Locatie

European Medicines Agency, Amsterdam, the Netherlands

The workshop is intended to discuss the draft guideline on similar biological medical products, the draft guideline on similar biological medical products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, and the draft guideline on similar biological medical products containing biotechnology-derived proteins as active substance: quality issues. Registration closed.

Documents

Agenda - Workshop on biosimilars

Reference Number: EMA/473908/2013

English (EN) (74.69 kB - PDF)

Publicatiedatum: Laatst gewijzigd:
Bekijk

List of participants - Workshop on biosimilars

Reference Number: EMA/681299/2013

English (EN) (143.9 kB - PDF)

Publicatiedatum: Laatst gewijzigd:
Bekijk

Presentation - Draft revised guideline on similar biological medicinal products: Relevant changes (Martina Weise)

English (EN) (234.06 kB - PDF)

Publicatiedatum: Laatst gewijzigd:
Bekijk

Presentation - EBG’s comments on the draft revised guideline on similar biological medicinal products (Karl Heinz Emmert)

English (EN) (1.09 MB - PDF)

Publicatiedatum: Laatst gewijzigd:
Bekijk

Presentation - Guideline on similar biological medicinal products: Overarching guideline

English (EN) (734.59 kB - PDF)

Publicatiedatum: Laatst gewijzigd:
Bekijk

Presentation - Guideline on similar biological medicinal products containing biotechnologically-derived proteins as active substances: quality issues (Niklas Ekman)

English (EN) (159.22 kB - PDF)

Publicatiedatum: Laatst gewijzigd:
Bekijk

Presentation - EGA’s perspective on the draft quality guideline (Joerg Windisch)

English (EN) (922.36 kB - PDF)

Publicatiedatum: Laatst gewijzigd:
Bekijk

Presentation - Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: Quality issues

English (EN) (656.89 kB - PDF)

Publicatiedatum: Laatst gewijzigd:
Bekijk

Presentation - Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (Niklas Ekman)

English (EN) (309.73 kB - PDF)

Publicatiedatum: Laatst gewijzigd:
Bekijk

Presentation - Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (Hans-Karl Heim)

English (EN) (117.28 kB - PDF)

Publicatiedatum: Laatst gewijzigd:
Bekijk

Presentation - Guideline on Similar biological medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues (Pekka Kurki)

English (EN) (360.9 kB - PDF)

Publicatiedatum: Laatst gewijzigd:
Bekijk

Presentation - EBG’s perspective on the draft guideline on the non-clinical/clinical issues (Mark McCamish)

English (EN) (1.18 MB - PDF)

Publicatiedatum: Laatst gewijzigd:
Bekijk

Presentation - Nonclinical and clinical considerations

English (EN) (571.74 kB - PDF)

Publicatiedatum: Laatst gewijzigd:
Bekijk

Multimedia

Share this page